dc.contributor.author | Evans, C | |
dc.contributor.author | Chasekwa, B | |
dc.contributor.author | Ntozini, R | |
dc.contributor.author | Humphrey, JH | |
dc.contributor.author | Prendergast, AJ | |
dc.date.accessioned | 2019-02-27T13:00:40Z | |
dc.date.available | 2019-02-27T13:00:40Z | |
dc.date.issued | 2016-09-24 | |
dc.identifier.citation | Evans, C., et al. (2016). "Head circumferences of children born to HIV-infected and HIV-uninfected mothers in Zimbabwe during the preantiretroviral therapy era." AIDS 30(15): 2323-2328. | en_US |
dc.identifier.issn | 0269-9370 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/55585 | |
dc.description.abstract | Objectives: To describe the head growth of children according to maternal and child
HIV infection status.
Design: Longitudinal analysis of head circumference data from 13 647 children
followed from birth in the ZVITAMBO trial, undertaken in Harare, Zimbabwe, between
1997 and 2001, prior to availability of antiretroviral therapy (ART) or cotrimoxazole
prophylaxis.
Methods: Head circumference was measured at birth, then at regular intervals through
24 months of age. Mean head circumference-for-age Z-scores (HCZ) and prevalence
of microcephaly (HCZ < 2) were compared between HIV-unexposed children,
HIV-exposed uninfected (HEU) children and children infected with HIV in utero
(IU), intrapartum (IP) and postnatally (PN).
Results: Children infected with HIV in utero had head growth restriction at birth. Head
circumference Z-scores remained low throughout follow-up in IP children, whereas
they progressively declined in IU children. During the second year of life, HCZ in the
PN group declined, reaching a similar mean as IP-infected children by 21 months of
age. Microcephaly was more common among IU and IP children than HIV-uninfected
children through 24 months. HEU children had significantly lower head circumferences
than HIV-unexposed children through 12 months.
Conclusion: HIV-infected children had lower head circumferences and more microcephaly than HIV-uninfected children. Timing of HIV acquisition; influenced HCZ,
with those infected before birth having particularly poor head growth. HEU children
had poorer head growth until 12 months of age. Correlations between head growth and
neurodevelopment in the context of maternal/infant HIV infection, and further studies
from the current ART era, will help determine the predictive value of routine head
circumference measurement | en_US |
dc.description.sponsorship | The ZVITAMBO trial was supported by the Canadian International Development Agency (CIDA) (R/C Project 690/M3688), United States Agency for International Development (USAID) (cooperative agreement number HRN-A-00–97-00015-00 between Johns Hopkins University and the Office of Health and Nutrition – USAID) and a grant from the Bill and Melinda Gates Foundation, Seattle, Washington, USA. Additional funding was received from the SARA Project that is operated by the Academy for Educational Development, Washington, District of Columbia, USA and is funded by USAID's Bureau for Africa, Office of Sustainable Development under the terms of Contract AOT-C-00-99-00237-00, the Rockefeller Foundation (New York, New York, USA) and BASF (Ludwigshafen, Germany). C.E. is funded by the National Institute for Health Research. A.J.P. is funded by the Wellcome Trust (108065/Z/15/Z). | en_US |
dc.format.extent | 2323 - 2328 | |
dc.language.iso | en | en_US |
dc.publisher | Lippincott, Williams & Wilkins | en_US |
dc.relation.ispartof | AIDS | |
dc.rights | Creative Commons Attribution License | |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject | Africa | en_US |
dc.subject | children | en_US |
dc.subject | head circumference | en_US |
dc.subject | HIV | en_US |
dc.subject | microcephaly | en_US |
dc.title | Head circumferences of children born to HIV-infected and HIV-uninfected mothers in Zimbabwe during the preantiretroviral therapy era | en_US |
dc.type | Article | en_US |
dc.rights.holder | 2016 Wolters Kluwer Health, Inc | |
dc.identifier.doi | 10.1097/QAD.0000000000001196 | |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383597700009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 15 | en_US |
pubs.notes | No embargo | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 30 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |
qmul.funder | The impact of cotrimoxazole on healthly birth and growth in rural Zimbabwe::Wellcome Trust | en_US |